| 益肾排毒方联合非布司他片治疗肾虚血瘀型尿酸性肾病临床研究 |
| Clinical study of Yishen Paidu Formula combined with febuxoat tablets in treating uric acid nephropathy of kidney deficiency and blood stasis type |
| DOI： |
| 中文关键词: 尿酸性肾病 益肾排毒方 肾虚血瘀型 非布司他 |
| 英文关键词: uric acid nephropathy Yishen Paidu Formula Kidney deficiency and blood stasis type Febuxostat |
| 基金项目:武汉市科技局科研项目(2023020201020556)；武汉市卫生健康委员会课题(WZ22Q51) |
|
| 摘要点击次数: |
| 全文下载次数: |
| 中文摘要: |
| 目的：研究益肾排毒方联合非布司他片治疗肾虚血瘀型尿酸性肾病的临床疗效。方法：纳入70例肾虚血瘀型尿酸性肾病患者,按照随机数表法将其分为观察组35人,对照组35人,予以对照组患者非布司他片治疗,观察组在对照组基础上再予中药益肾排毒方治疗,疗程为12周。观察并记录两组患者治疗后的临床疗效,治疗前后中医证候评分变化,治疗前后血尿酸(UA)、血肌酐(Scr)、尿素氮(BUN)、胱抑素C(Cys-C)、24h尿蛋白(24 h Upro)、β2-微球蛋白(β2-MG)指标变化以及治疗过程中不良反应发生率。结果：观察组的总有效率(90.14％)显著高于对照组(66.08％),差异有统计学意义(P<0.05)。治疗后两组的中医症状评分均降低(P＜0.05),且观察组低于对照组,差异有统计学意义(P＜0.05)。治疗后两组UA、BUN、Scr、Cys-C水平均低于治疗前,eGFR高于治疗前,差异有统计学意义(P＜0.05)；治疗后观察组UA、BUN、Scr、Cys-C水平均低于对照组,eGFR高于对照组,差异有统计学意义(P＜0.05)。治疗后两组24 h Upro、β2-MG水平均低于治疗前,差异有统计学意义(P＜0.05)；治疗后观察组24 h Upro、β2-MG水平均低于对照组,差异有统计学意义(P＜0.05)。治疗过程中,观察组不良反应发生率为5.7％,对照组为2.8％, 差异无统计学意义(P＞0.05)。结论：益肾排毒方联合非布司他片治疗肾虚血瘀型尿酸性肾病疗效显著,能够改善患者肾功能,降低24 h Upro、β2-MG水平,缓解临床症状,且具有良好的安全性,临床值得推广。 |
| 英文摘要: |
| Objective: To study the clinical efficacy of Yishen Paidu Formula(益肾排毒方) combined with Febuxosita tablet in the treatment of uric acid nephropathy with kidney deficiency and blood stasis. Methods: 70 patients with renal deficiency and blood stasis type uric acid nephropathy were included and divided into observation group (35) and control group (35) according to random number table method. The control group was treated with feburestat tablets, and the observation group was treated with Yishen Paidu Formula on the basis of the control group. The course of treatment was 12 weeks. Observe and record the clinical efficacy of the two groups of patients after treatment, and the change of TCM syndrome score before and after treatment. Changes of UA, Scr, BUN, Cys-C, 24h Upro, β2-MG indexes before and after treatment and the incidence of adverse reactions during treatment. Results: The total effective rate of observation group (90.14%) was significantly higher than that of control group (66.08%), and the difference was statistically significant (P < 0.05). After treatment, the TCM symptom scores of both groups were decreased (P < 0.05), and the observation group was lower than the control group, the difference was statistically significant (P < 0.05). After treatment, the levels of UA, BUN, Scr and Cys-C were lower than before treatment, and eGFR was higher than before treatment, the difference was statistically significant (P < 0.05). After treatment, the levels of UA, BUN, Scr and Cys-C in observation group were lower than those in control group, and eGFR was higher than that in control group, the difference was statistically significant (P < 0.05). The 24 h Upro and β2-MG levels after treatment were lower than before treatment, and the difference was statistically significant (P < 0.05). After treatment, 24 h Upro and β2-MG levels in the observation group were lower than those in the control group, and the difference was statistically significant (P < 0.05). In the course of treatment, the incidence of adverse reactions was 5.7% in the observation group and 2.8% in the control group, the difference was not statistically significant (P > 0.05). Conclusion: Yishen Paidu Formula combined with Febuxosita tablet has significant efficacy in the treatment of renal deficiency and blood stasis type uric acid nephropathy, which can improve renal function, reduce 24 h Upro and β2-MG levels, relieve clinical symptoms, and has good safety, which is worthy of clinical promotion. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|